Panasonic and Institute of Microchemical Technology Co., Ltd. Jointly Develop Mass Production Technology for Microfluidic Devices by Glass Molding, a First in the Industry*1
6.11.2019 05:17:00 EET | Business Wire | Press release
Panasonic Corporation (Panasonic) and Institute of Microchemical Technology Co., Ltd. (IMT) jointly developed a technology for mass production of microfluidic devices*2 using a glass molding. Compared to the conventional glass etching method, this technology realizes low cost (about 1/10) and highly accurate (about 10 times) mass production. These devices can be applied to sensing and analysis for medical, biological, environmental (water and air quality) applications, etc. The companies will start accepting prototype orders from FY2019, and are planning to start mass production from FY2020. Panasonic and IMT will present and exhibit this device at the 40th meeting of Society for Chemistry and Micro-Nano Systems (CHEMINAS 40th) held at Act City Hamamatsu in Hamamatsu City, Shizuoka Prefecture, Japan from November 19th to 21st.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191105006302/en/
Microfluidic device technology (Graphic: Business Wire)
[Effect]
Conventional glass microfluidic devices have not been widely used, because of high cost and poor precision. This development achieved mass production and cost reduction of glass microfluidic devices by combining IMT's microfluidic device design technology and Panasonic's glass molding technology. As a result, disposable use of glass microfluidic devices becomes possible. In addition, by realizing high precision, it is easy to incorporate the device as a part of equipment and systems.
[Application]
By taking advantage of the environmental and chemical resistance of glass microfluidic devices, it can be applied to environmental sensing, blood testing, and pharmaceutical equipment as disposable detection devices for analysis and testing in outdoor and harsh environments.
[Characteristic]
The newly developed microfluidic device has the following features.
1. Up to φ50mm size
2. More than 10,000 devices per month of production capacity
3. Manufacturing process with the shape precision of about 1μm
[Technology]
This development is realized by the following technologies.
(1) Design and interface technology of microfluidic device optimized for glass molding
(2) Microstructure mold processing technology to higher hardness material and microstructural glass molding technology to precisely transfer to glass
(3) Thermal bonding technology to join a flat glass plate and a plate with microstructures.
Notes:
*1: As of November 6, 2019, Panasonic survey
*2: A device that can perform various chemical processes (mixing, reaction, extraction, synthesis, detection) in a minute flow path with a small amount and high efficiency by flowing liquid through a groove with a width and depth of several hundreds of micrometers.
[Background]
General microfluidic device made of glass used in microfluidics technology [1] is mainly produced by etching techniques. After drawing the flow path pattern by photolithography, the glass flow path is formed by etching, and the cover glass with the machined introduction hole is bonded. Since the inception of this field, IMT has provided high-level products as a pioneer in the planning, design and manufacture of glass microfluidic devices. However, in addition to the skill required for manual manufacturing, the manufacturing process took several months. For this reason, the manufacturing time and cost per piece became a hurdle, and generalization and industrial mounting were not realized, and the use was limited mainly to basic research applications.
On the other hand, Panasonic has been developing and manufacturing glass molding technology [2] from the 1980s, that has contributed to the commercialization of the world's highest level of optical device. They are used in lenses for various optical devices, like digital still cameras.
By combining Panasonic's glass molding technology and IMT design technology, it became possible to develop microstructure mold machining technology, molding technology, and joining technology suitable for mass production of microfluidic devices using glass molding technology. The companies have succeeded in developing mass production technology for microfluidic devices. As a result, it is possible to reduce the cost to about 1/10 compared to the conventional manufacturing method, and to supply glass microfluidic devices with improved precision 10 times or more in less than half the delivery time.
[Practical realization]
With the development of mass production technology for microfluidic devices [3] using this glass molding technology, glass microfluidic devices are widely used as disposable detection devices for analysis and testing in outdoor and harsh environments, and for disposable devices for blood testing equipment.
[Explanation of terms]
[1] Microfluidic device technology
This technology integrates chemical processes such as mixing, reaction, separation, extraction, synthesis, and detection in a flow channel of several tens to several hundreds of μm created on a substrate (microfluidic device) of several cm square. By freely integrating chemical processes that have been performed in laboratories and factories in the microspace of microfluidic devices, it becomes possible to use energy and space much more efficiently. It is expected to contribute greatly to the evolution of chemical technology in the future. This chemical process integration technology (microfluidic technology) in the micro space was established as a result of research and development of the Kitamori “Integrated Chemistry” project. The project was carried out at Kitamori Lab., Department of Applied Chemistry, School of Engineering, The University of Tokyo, and Kanagawa Academy of Science and Technology (currently Kanagawa Institute of Industrial Science and Technology).
[2] Glass molding technology (mold machining technology, mold protection coating technology, molding technology)
[3] Application examples of microfluidic devices using glass molding technology
About Panasonic
Panasonic Corporation is a worldwide leader in the development of diverse electronics technologies and solutions for customers in the consumer electronics, housing, automotive, and B2B businesses. The company, which celebrated its 100th anniversary in 2018, has expanded globally and now operates 582 subsidiaries and 87 associated companies worldwide, recording consolidated net sales of 8.003 trillion yen for the year ended March 31, 2019. Committed to pursuing new value through innovation across divisional lines, the company uses its technologies to create a better life and a better world for its customers. To learn more about Panasonic: https://www.panasonic.com/global.
About Institute of Microchemical Technology
IMT is a pioneer company of microchemical chip technology (microfluidics) and was founded in 2001 as a venture company of the University of Tokyo and Kanagawa Institute of Industrial Science and Technology (formerly Kanagawa Academy of Science and Technology).
IMT manufactures and sells microchemical chips, their peripheral equipment and system devices.
Company Name: Institute of Microchemical Technology Co., Ltd (IMT)
Capital: 100M JPY
Foundation: May 1st, 2001
Address: A-19 AIRBIC, 7-7 Shinkawasaki, Saiwai, Kawasaki, Kanagawa 212-0032 Japan
TEL: +81-44-201-9889 FAX: +81-44-201-9890
HP: https://www.i-mt.co.jp/en/
Source: https://news.panasonic.com/global/press/data/2019/11/en191106-3/en191106-3.html
Related Links
Industrial Devices & Solutions - Panasonic
https://industrial.panasonic.com/ww
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191105006302/en/
Contact information
Panasonic
Innovation Strategy Office
Technology Public Relations Section
crdpress@ml.jp.panasonic.com
[Inquiries for prototypes]
Institute of Microchemical Technology Co., Ltd.
Email:info@i-mt.co.jp Tel: +81-44-201-9889
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
